|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.50 HKD | +4.44% |
|
-4.73% | +23.58% |
| 05-11 | Henlius Gets US FDA's Nod for Clinical Trial for HLX05-N | MT |
| 05-11 | Henlius Biotech Gets European Commission's Nod for Hetronifly | MT |
| Capitalization | 33.31B 38.32B 4.89B 4.2B 3.85B 3.65B 6.73B 471B 6.84B 46.04B 17.84B 223B 18.36B 17.97B 777B | P/E ratio 2026 * |
32.8x | P/E ratio 2027 * | 34.8x |
|---|---|---|---|---|---|
| Enterprise value | 33.08B 38.05B 4.86B 4.17B 3.82B 3.63B 6.68B 468B 6.79B 45.72B 17.72B 221B 18.24B 17.85B 772B | EV / Sales 2026 * |
4.23x | EV / Sales 2027 * | 4.35x |
| Free-Float |
16.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Shanghai Henlius Biotech, Inc.
| 1 day | +4.44% | ||
| 1 week | -4.73% | ||
| Current month | -6.25% | ||
| 1 month | -16.52% | ||
| 6 months | +10.50% | ||
| Current year | +23.58% |
| 1 week | 66 |  | 72.25 |
| 1 month | 66 | | 84.95 |
| Current year | 53.05 | | 87.1 |
| 1 year | 39.7 | | 92 |
| 3 years | 9.6 | | 92 |
| 5 years | 9.6 | | 92 |
| 10 years | 9.6 | | 92 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun Zhu
CEO | Chief Executive Officer | 48 | 17/07/2023 |
Wei Dong Jiang
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/2009 |
Yingbo Mao
DFI | Director of Finance/CFO | 48 | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
CHM | Chairman | 54 | 01/12/2018 |
Xiao Hui Guan
BRD | Director/Board Member | 55 | 24/12/2018 |
Rui Lin Song
BRD | Director/Board Member | 63 | 02/09/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.44% | -4.73% | +78.03% | +453.38% | 4.69B | |
| -9.82% | -11.66% | +5.95% | -15.76% | 71.04B | |
| -3.00% | -2.50% | +45.00% | +164.74% | 52.43B | |
| -2.33% | +38.60% | +38.60% | +38.60% | 43.84B | |
| +1.76% | -0.28% | -59.36% | -67.72% | 33.99B | |
| -0.54% | -3.05% | +52.81% | -37.17% | 28.49B | |
| -1.90% | -9.02% | +93.52% | -61.61% | 19.46B | |
| -0.13% | -5.11% | +50.36% | +49.60% | 19.04B | |
| -2.07% | -9.01% | +57.45% | +111.87% | 18.17B | |
| -1.54% | -2.21% | +41.16% | +87.64% | 16.16B | |
| Average | -1.48% | -6.94% | +40.35% | +72.36% | 30.73B | |
| Weighted average by Cap. | -3.19% | -7.46% | +28.68% | +36.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.81B 8.99B 1.15B 986M 902M 857M 1.58B 111B 1.6B 10.8B 4.19B 52.32B 4.31B 4.22B 182B | 7.52B 8.65B 1.1B 949M 868M 824M 1.52B 106B 1.54B 10.39B 4.03B 50.34B 4.14B 4.06B 175B |
| Net income | 1.02B 1.17B 149M 128M 117M 111M 205M 14.37B 209M 1.4B 544M 6.8B 560M 548M 23.71B | 956M 1.1B 140M 121M 110M 105M 193M 13.53B 196M 1.32B 512M 6.4B 527M 516M 22.31B |
| Net Debt | -230M -264M -33.72M -28.97M -26.51M -25.17M -46.35M -3.25B -47.14M -317M -123M -1.54B -127M -124M -5.36B | -631M -725M -92.63M -79.59M -72.82M -69.16M -127M -8.92B -130M -872M -338M -4.22B -348M -340M -14.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/05/26 | 70.50 $ | +4.44% | 927,336 |
| 15/05/26 | 67.50 $ | +0.22% | 726,309 |
| 14/05/26 | 67.35 $ | -2.39% | 466,270 |
| 13/05/26 | 69.00 $ | -4.17% | 639,151 |
| 12/05/26 | 72.00 $ | -2.70% | 1,069,574 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2696 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition